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Abstract
The age-related loss of anti-oxidant defense reduces recovery from myocardial ischemia/reperfusion injury
(MI/R) in aged people. Our previous data showed that inactivation of thioredoxin (Trx) was involved in
enhanced aging MI/R injury. Thioredoxin reductase (TrxR), the enzyme known to regulate Trx, is less efficient
with age. The aim of the current study was to determine why TrxR activity was reduced and whether reduced
TrxR activity contributed to enhanced aging MI/R injury. Both Trx and TrxR activity were decreased in the
aging heart, and this difference was further amplified after MI/R. However, MI/R injury did not change TrxR
expression between young and aging rats. Increased nitrogen oxide (NOx) but decreased nitric oxide (NO)
bioavailability (decreased phosphorylated vasodilator-stimulated phosphoprotein) was observed in aging
hearts. Peroxynitrite (ONOO - ) was increased in aging hearts and was further amplified after MI/R. TrxR
nitration in young and aging hearts was detected by immunoprecipitation (anti-nitrotyrosine) followed by
immunoblotting (anti-TrxR). Compared with young hearts, TrxR nitration was increased in the aging hearts, and
this was further intensified after MI/R. The ONOO - decomposition catalyst (FeTMPyp) reduced TrxR nitration
and increased TrxR and Trx activity. More importantly, FeTMPyp attenuated the MI/R injury in aging hearts as
evidenced by decreased caspase-3 and malondialdehyde (MDA) concentration and increased cardiac function.
Increased ONOO - nitrated TrxR in the aging heart as a post-translational modification, which may be related to
the enhanced MI/R injury of aging rats. Interventions that inhibit nitration and restore TrxR activity might be a
therapy for attenuating enhanced MI/R injury in aging heart.
Introduction
The incidence and prevalence of ischemic heart dis-ease increases progressively with age, and both devel-
oped and developing countries are faced with an
increasingly aging population.1 Not only is there an in-
creased ischemia/reperfusion injury related risk factor with
aging, but there is also the possibility of a loss of endogenous
protection against myocardial ischemia/reperfusion (MI/R)
injury.2 However, the mechanisms responsible for this age-
related loss of endogenous protection remain elusive.
Reactive oxygen species (ROS) have long been recognized
to act as the major mediator of the aging process and to play
critical roles in increased susceptibility of post-ischemic
myocardial apoptosis in aging.3,4 However, the outcome of
clinical trials with anti-oxidant treatment during myocardial
ischemia and reperfusion has been rather disappointing,5
suggesting that other factors in addition to ROS exist. In
aging hearts, high levels of nitric oxide (NO) are converted to
a number of more reactive derivatives, known collectively as
reactive nitrogen species (RNS).6 Peroxynitrite (ONOO - ), an
extremely important RNS, is a highly reactive species and
oxidizes or nitrates (e.g., tyrosine nitration) a variety of
molecules, and this has been shown to induce cardiomyocyte
death.7 The glutathione (GSH) anti-oxidant system has been
demonstrated to be a defense against ONOO- . In addition to
the GSH system, most recent studies suggest that the thior-
edoxin (Trx) system works with the GSH system in a parallel
fashion in anti-oxidant defense mechanisms.8 Our previous
work reported that Trx activity is decreased in the aging
heart by post-transcriptional nitrated modification, which is
involved in aging-enhanced MI/R injury.9 Besides the ni-
trated modification, there were many reasons contributing to
inactivation of Trx. Growing evidence has shown that the
Trx reductase (TrxR) was found as the key enzyme known to
maintain the activity of Trx.10 Mutations in TrxR genes have
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been identified as causing dilated cardiomyopathy, and new
reports showed that TrxR exerts a crucial function during
post-ischemic reperfusion.11,12 In 2006, Rohrbach et al. re-
ported that the activity of TrxR was decreased in the aging
heart. Meanwhile, decreased TrxR expression enhanced the
susceptibility to apoptotic stimuli in in vitro experiments.13
However, why TrxR was inactivated and whether this al-
teration may involve in aging MI/R injury requires further
investigation.
In vitro studies showed that the hexavalent chromium
[Cr(VI)]-mediated inhibition of TrxR continues after it is
removed, suggesting the modification of TrxR is not easily
reversed. Cr(VI) causes increased ONOO- generation, which
results in nitrotyrosine modifications to proteins.14,15 High
levels of ONOO - exist in the aging heart and might nitrate
some proteins, such as TrxR. However, there is a lack of
direct evidence demonstrating that TrxR was nitrated and
that the nitrated TrxR contributed to its inactivation.
Therefore, the aims of the present study were to: (1) De-
termine whether TrxR was inactivated in the aging heart
subjected to MI/R injury; (2) study whether the inactivation
of TrxR was related to its nitration with the high concen-
tration of ONOO- in the aging heart subjected to MI/R in-
jury; and (3) investigate whether treatment with FeTMPyp
(ONOO - decomposition catalyst) reduced the nitrated TrxR
and attenuated the MI/R injury in aging rats.
Materials and Methods
Animals
All of the investigations conformed to the ‘‘Guiding
Principles in the Use and Care of Animals’’ published by the
National Institutes of Health (NIH Publication No. 85-23,
Revised 1996) and approved by the Institutional Animal
Care and Use Committee of Capital Medical University. We
obtained 6- to 8-month-old (young) and 20- to 24-month old
(aging) male Sprague–Dawley rats for the experiment.
Experimental protocol
Sprague–Dawley rats were anesthetized with chloral hy-
drate (400mg/kg). Myocardial ischemia was produced by
exteriorizing the heart via a left thoracic incision and oc-
cluding the left coronary artery (LCA) with a 6-0 silk slip-
knot. After 30min of ischemia, the slipknot was released and
the myocardium was reperfused for 3 hr. The sham-operated
control rats (sham) underwent the same surgical procedures
except that the LCA was not occluded. Animals were ran-
domized to treat with vehicle (saline) or FeTMPyp (Cayman
Chemical, CAS 133314-07-5) via intraperitoneal injection
10min prior to reperfusion.
Determination of myocardial ischemia/reperfusion-
related injury
Determination of ventricular function. Left ventricular
(LV) function was continuously monitored via a MillarMikro-
Tip catheter pressure transducer inserted into the LV via the
left carotid artery (Powerlab Hardware; AD Instruments,
Charlotte, NC). Left ventricular end diastolic pressure
(LVEDP), left ventricular systolic pressure (LVSP), and
maximal rate of rise/decrease of left ventricular pressure
(–dp/dtmax) were derived by computer algorithms.
Determination of caspase-3 protease activity. The sub-
strate Ac-DEVD-AFC (Enzo Life Sciences) was used to de-
termine caspase-3 activity according to the manufacturer’s
instructions. In brief, 30mg of myocardial tissue blocks were
homogenized in ice-cold lysis buffer and centrifuged at
12,000 rpm for 10min at 4C. A 50-lL amount of supernatant
was then incubated with buffer containing 10mM dithio-
threitol (DTT) and 5lL Ac-DEVD-AFC (the final concentra-
tion was 200lM) at 37C for 1.5 hr. Activity of caspase-3 was
determined using a fluorescent microplate reader (BIOTEK,
FL-600) at Ex 400 nm, Em 508 nm, and the results were ex-
pressed as -fold of the Sham/Vehicle group.
Measurement of malondialdehyde concentra-
tion. Malondialdehyde (MDA) concentration is a widely
used method to analyze lipid peroxidation in biological
material. Cardiac homogenate (10%, wt/vol) was prepared
with 0.1M phosphate-buffered saline (PBS) and centrifuged
at 1200 · g for 10min. The supernatant was used to deter-
mine MDA concentration with commercially available kits
(Nanjing Jiancheng Bioengineering Institute, China).
Detection of total NO and nitrotyrosine content in cardiac
tissue. NO has a short half-life and is oxidized to form NO2
and NO3 in vivo. Thus, the detection of NOx (NO˙ +NO2 +
NO3) concentration has been demonstrated to reflect total
NO formation in vivo. Cardiac tissue samples from risk areas
were rinsed and homogenized in deionized water (10%, wt/
vol) and centrifuged at 12000 rpm for 10min. The tissue NO
and its in vivo metabolic products (NO2 and NO3) in the
supernatant, collectively known as NOx, were determined
using a chemiluminescence NO detector (SIEVER 280i NO
Analyzer; Ionics Instruments, Boulder, CO), as described in
our previous study.9 Nitrotyrosine content has been exten-
sively used by many investigators as a marker for ONOO- ,
which was determined using an enzyme-linked immuno-
sorbent assay (ELISA) method described in our previous
publication.9
Trx and TrxR activity assay. The insulin disulfide re-
duction assay was used to detect the Trx activity. In brief,
50 lg of cellular protein extracts were pre-incubated at 37C
for 15min with 2 lL activation buffer (100mM HEPES, 2mM
EDTA, 1mg/mL bovine serum albumin [BSA], and 2mM
DTT) to reduce Trx. After addition of 20 lL reaction buffer
(100mM HEPES, 2.0mM EDTA, 0.2mM nicotinamide ade-
nine dinucleotide phosphate [NADPH], and 140 lM insulin),
the reaction was started by the addition of mammalian Trx
reductase (1lL, 15mU, Sigma) or water to controls and sam-
ples incubated for 30min at 37C. The reaction was terminated
by adding 125lL of stopping solution (0.2M Tris-Cl, 10M
guanidine-HCl, and 1.7mM 3-carboxy-4-nitrophenyl disulfide,
1mM dinitrothiocyanobenzene (DTNB) followed by absorption
measurement at 412nm. Myocardium supernatants were nor-
malized for total protein content via Bradford assay before
determination of TrxR activity by a TrxR activity assay kit
(ab83463, Abcam) according to the manufacturer’s instructions.
Detection of TrxR protein expression and TrxR nitra-
tion. Western blotting was used for detecting TrxR1 and
TrxR2 proteins, as described previously.2 Briefly, 80 lg of
protein was loaded, and the primary antibodies used were
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mouse anti-TXNRD1 (ab16847, Abcam) and rabbit anti-
TXNRD2 (ab58445, Abcam). The density of the scanned
protein bands was measured by image analysis software,
and the results were presented as percentage change of the
loading control. Immunoprecipitation and immunoblotting
were performed by using a procedure described by Ischir-
opoulos et al.16 Nitrotyrosine was immunoprecipitated with
a monoclonal anti-murine 3-nitrotyrosine antibody (ab61392,
Abcam). After sample separation, TrxR nitration was de-
tected with a monoclonal antibody against TrxR1 and TrxR2.
The blot was developed with Supersignal-Western reagent
(Pierce) and visualized with a Kodak Image Station 400.
Statistical analysis. All data were described as
mean – standard error of the mean (SEM). Statistical analysis
was performed with SPSS 15.0 programs. The t-test was used
to compare two independent sample means, and one-way
analysis of variance (ANOVA) was used for comparing
means of more than two samples. All aging and young rats
were randomly assigned to different experiments. A p value
of < 0.05 was considered to be statistically significant.
Results
Aging rat hearts were more susceptible to myocardial
ischemia/reperfusion injury
Consistent with previously published results by us and
other investigators, aging rat hearts showed more suscepti-
bility to myocardial ischemia/reperfusion injury as evi-
denced by exaggerated cardiac dysfunction, increased
apoptosis and MDA concentration9,17 (Fig. 1).
Age-related TrxR activity was decreased in rat hearts
subjected to MI/R
Accumulating evidence indicates that the Trx/TrxR system
participates in limiting MI/R, apoptosis, and infarct size.11,18
FIG. 1. Aging rat hearts were more susceptible to myocardial ischemia/reperfusion injury. (A) Comparison of left ven-
tricular systolic pressure (LVSP) in both the young rats and aging rats after myocardial ischemia/reperfusion (MI/R). (B) Left
ventricular end diastolic pressure (LVDEP). (C and D) Maximal rate of rise/decrease of left ventricular pressure ( –dp/
dtmax). (E) MI/R-induced cardiomyocytes apoptosis with aging. Activity of caspase-3 was determined at the end of re-
perfusion. (F) Malondialdehyde (MDA) concentration. MI/R indicates myocardial ischemia for 30min and reperfusion for
3 hr. The Sham group underwent the same surgical procedures except that the left coronary artery was not occluded. Data are
expressed as mean – standard error of the mean (SEM) (n= 6–8 each). (*) p< 0.05, (**) p< 0.01 vs. Sham; (#) p< 0.05 vs. Young.
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As summarized in Fig. 2A, compared with young rats, cardiac
Trx activity showed a gradual decrease during aging, and this
difference was further amplified after MI/R. TrxR was the
only enzyme known to catalyze the reduction of Trx and
hence is a central component in the Trx system. Thus, TrxR
activity was determined. It was shown that cardiac TrxR ac-
tivity in aging rats was lower than that in the young rats.
Moreover, the TrxR activity decreased in aging hearts after
MI/R and was lower than that in young adult hearts sub-
jected to MI/R (Fig. 2B). Two major kinds of TrxR protein
expression, including TrxR1 and TrxR2, were detected. As
shown in Fig. 2C, there was no statistical significance of car-
diac TrxR1 protein expression between young and aging rats,
whereas TrxR2 protein expression was decreased in Fig. 2D.
Moreover, MI/R injury did not change both TrxR1 and TrxR2
expression between the young and aging groups.
Production of ONOO - was increased in aging
hearts subjected to MI/R
A large number of studies suggest that markedly increased
NO and decreased bioavailability are considered to be one of
the most important mechanisms that results in age-related
cardiac dysfunction.19 Concentrations of NOx (NOx=NO˙+
NO2+NO3) were measured by using the previously reported
vanadium reduction method.9 Our results showed that young
adult hearts had a low basal NOx, and aged hearts had a
markedly increased basal NOx compared to young adult
hearts (Fig. 3A). In vivo vasodilator-stimulated phosphopro-
tein (VASP) phosphorylation reflected NO bioavailability.20
As illustrated in Fig. 3B, our data demonstrated that although
total VASP levels are comparable in both groups, phosphor-
ylated VASP (p-VASP) is markedly reduced in heart tissues
isolated from aged rats. Therefore, we believed increased NO
contributed to the production of ONOO- with higher su-
peroxide generation in aging. The detection of tissue ni-
trotyrosine content has been extensively used by many
investigators as a marker for ONOO- . As illustrated in Fig.
3C, more nitrotyrosine was detected in myocardial tissue from
aging rats compared with young adult rats. Moreover, is-
chemia/reperfusion-induced overproduction of ONOO- was
further amplified in the aging heart.
Cardiac TrxR was nitrated in aging rats,
which was involved in its inactivation
Protein nitration has been shown to be a post-translational
protein modification process. We wanted to determine
whether reduced TrxR activity observed in the aging heart is
caused by increased nitrative stress and subsequent TrxR
nitration. First, the TrxR nitration in young and aging hearts
was detected by immunoprecipitation (anti-nitrotyrosine)
followed by immunoblotting (anti-TrxR). As illustrated in
Fig. 4, A and B, nitrated TrxR was not detected in myocardial
FIG. 2. Age reduced efficiency of thioredoxin (Trx) system in the myocardium. (A and B) Both Trx activity and thioredoxin
reductase (TrxR) activity were significantly reduced in the aging rat heart either before or after myocardial ischemia/
reperfusion (MI/R). (C) Age-dependent differences in TrxR1 protein expression. (D) Age-dependent differences in TrxR2
protein expression. Densitometry analysis for expression of TrxR1 and TrxR2 protein by western blot (n = 8 each). Bar heights
represent mean values and brackets indicate standard error of the mean (SEM). (*) p < 0.05, (**) p < 0.01 vs. Sham; (#) p < 0.05
vs. Young. SY, Sham young; SA, Sham aged; RY, reperfused young; RA, reperfused aged.
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tissue from a young adult heart, but a clear nitrated band
was detected in the hearts of aged rats. Moreover, aging-
induced TrxR nitration was further intensified after ischemia/
reperfusion. We then determined whether the nitrative
modification resulted in TrxR inactivation. Treatment with
the peroxynitrite decomposition catalyst FeTMPyp blocked
TrxR nitration (Fig. 4C) and attenuated its activity (Fig. 4D).
Meanwhile, FeTMPyp restored Trx activity in the aging heart
subjected to MI/R (Fig. 4E).
Treatment with the peroxynitrite decomposition
catalyst FeTMPyp exerted significant cardiac
protective effects against MI/R injury in the aging heart
The data above show that MI/R caused more TrxR ni-
tration in the aging heart, so we then sought to determine
whether the TrxR nitration induced more serious aging post-
ischemic myocardial injury. As shown in Fig. 5, A and B,
FeTMPyp treatment significantly attenuated caspase-3 ac-
tivity and MDA concentration in the aging heart subjected to
MI/R. To determine whether the cardioprotective effects of
FeTMPyp were sustained, aging rats were subjected to
30min of ischemia and 3h of reperfusion, and the effect of
FeTMPyp on cardiac function was determined. As summa-
rized in Fig. 5, C and D, treatment with FeTMPyp
restored –dp/dtmax, but not LVSP and LVEDP.
Discussion
Baseline cardiac function declines with aging. When the
aged heart is exposed to various forms of stress, an ampli-
fication of MI/R injury is observed. Higher oxidative stress
and lower oxidation defense capabilities are involved in
amplified aging MI/R injury. In the present study, we de-
fined for the first time that the enzyme responsible for pro-
tein thiol oxidation repair, TrxR, becomes less efficient in
the aging heart and even much less efficient after MI/R.
Moreover, we have demonstrated that it was the post-
translational nitrative modification of TrxR that is responsi-
ble for this reduced TrxR activity in the aging heart subjected
to MI/R. Finally, we have demonstrated that treatment with
a peroxynitrite decomposition catalyst shortly before re-
perfusion blocked nitrative TrxR inactivation–attenuated
aging MI/R injury. Taken together, these results provide
strong evidence that nitrative TrxR inactivation might be
involved in enhanced aging MI/R injury.
Excessive formation of ROS during post-ischemic reperfu-
sion significantly contributes to tissue injury and functional
deterioration of the heart. MI/R injury has been shown to be
attenuated by endogenous ROS scavenging systems, such as
mitochondrial manganese superoxide dismutase, detoxifying
O2, and catalase or GSH peroxidase.
20 Growing evidence
showed that besides the GSH system, the Trx system, includ-
ing Trx, TrxR, Trx peroxidase, and NADPH, was a ubiquitous
thiol oxidoreductase system that regulates cellular reduction/
oxidation (redox) status and cell proliferation/cell survival.21
In 2007, our previous study reported that aging-induced
Trx inactivation was one of the causes of enhanced aging
MI/R injury.9 However, Trx is directly dependent on TrxRs,
which reduce the active site of Trx from the disulfide form
to the biologically active dithiol form. TrxR inhibition
FIG. 3. Aging enhances nitrative stress in the heart subjected to myocardial ischemia/reperfusion (MI/R). (A) Total NOx
production was increased in the aging heart. (B) Phosphorylated vasodilator-stimulated phosphoprotein (p-VASP) was
reduced in heart tissues isolated from aged rat. (C) Nitrotyrosine content, as a marker for ONOO- , was increased in aging rat
heart either before or after MI/R. (*) p< 0.05, (**) p< 0.01 vs. Sham; (#) p< 0.05, (##) p < 0.01 vs. Young.
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enhances oxidant susceptibility and favors apoptosis. TrxR
was markedly up-regulated in cancer tissues, and molecules
that inhibit TrxR promote apoptosis and reduce cancer
development.22
Our current results illustrate that the activity of TrxR was
decreased in the aging heart, which might contribute to Trx
inactivation. In mammals, there are three TrxR isoforms.
Thioredoxin reductase-1 (TrxR1) is localized primarily in the
cytosol, whereas thioredoxin reductase-2 (TrxR2) is expressed
in the mitochondria.11 A third form, thioredoxin reductase-3,
is mainly expressed in the testis, and thus, was not included in
the current study. We found TrxR1 protein expression was not
significantly different in the hearts of the aging rat compared
with the young adults, whereas TrxR2 protein expression was
significantly decreased. These results were consistent with the
study of Rohrbach et al., which suggested that aging is char-
acterized by a specific reduction of TrxR2 and results in the
sensitization of cells to oxidative challenge and increased
FIG. 4. The inactivation of thioredoxin reductase (TrxR) was related to its nitration. TrxR nitration in young and aging
hearts was detected by immunoprecipitation (anti-nitrotyrosine) followed by immunoblotting (anti-TrxR). Nitration of
TrxR1 (A) and TrxR2 (B) in the aging heart subjected to myocardial ischemia/reperfusion (MI/R). The peroxynitrite
decomposition catalyst FeTMPyp decreased the nitration of TrxR1 (C) and attenuated its activity (D). (E) Treatment with
FeTMPyp attenuated Trx activity in the aging heart subjected to MI/R. Ten minutes before reperfusion, aging rats were
randomized to receive vehicle (saline) or FeTMPyp via intra-peritoneal injection (IP). (*) p < 0.05 vs. Sham; (#) p < 0.05 vs.
Young; (D) p < 0.05, (DD) p < 0.01 vs. Vehicle. IB, immunoblot; SY, Sham young; SA, Sham aging; RY, reperfused young; RO,
reperfused old; V, vehicle; Fe, FeTMPyp.
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susceptibility of the mitochondrial pathway of apoptosis.13,23
However, our results showed that ischemia/reperfusion
injury did not result in these age-related protein expression
changes of TrxR1 and TrxR2. Recent data has suggested
that there are no alterations in TrxR1 mRNA or protein
expression, but caloric restriction recovers TrxR1 activity in
senescent cardiac muscles.23 Both our results and those of
others have suggested that the regulation of age-related
TrxR activity may not be dependent on TrxR protein
expression.
Recent studies have demonstrated that besides up-regulation
or down-regulation of TrxR expression, TrxR activity was
regulated by post-translational modification. In the 1990s, it
was found that selenocysteine incorporation increased TrxR
activity without an increase in protein synthesis.21 However,
there have been few reports of TrxR modification in the past
10 years. There were multiple redox active sites within TrxR,
including the flavin adenine dinucleotide (FAD), the car-
boxy-terminal active site, and the amino-terminal domain
dithiol. All of these sites are necessary for electron flow, and
therefore TrxR activity and disruption of any one of these
could theoretically inhibit its activity.24 Meanwhile, there
were many tyrosine residues in TrxR, such as Tyr-114, Tyr-
116, and Tyr-200. It is noteworthy that Tyr-200 shields FAD
from the solvent and hinders proper binding of the nicotin-
amide ring of NADP + .25 Growing evidence has shown that
Trx can also be modified at the tyrosine residue (protein
nitration) in a ONOO - -dependent fashion.26,27 Thus, it was
reasonable to speculate the tyrosine residue in TrxR could be
nitrated with high levels of ONOO- in the aging heart.
FIG. 5. FeTMPyp attenuated the myocardial ischemia/reperfusion (MI/R) injury in the aging rats. Effect of FeTMPyp on
caspase-3 activity (A) and malondialdehyde (MDA) concentration (B) in the aging heart subjected to MI/R. (C) Effects of
FeTMPyp on left ventricular systolic pressure (LVSP) in the aging heart subjected to MI/R. (D) Left ventricular end diastolic
pressure (LVDEP). (E and F) Maximal rate of rise/decrease of left ventricular pressure (–dp/dtmax). Ten minutes before
reperfusion, rats were randomized to receive vehicle (saline) or FeTMPyp via intraperitoneal injection (IP). Data expressed as
mean – standard error of the mean (SEM) (n = 8 each). (D) p< 0.05, (DD) p < 0.01 vs. Vehicle.
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Our study reveals the first evidence of the TrxR nitration
in the heart of aging rats subjected to MI/R. However, in this
paper the exact tyrosine residues were not tested; they will
be investigated in future studies. Moreover, our results
suggested that high levels of NO are converted to the more
toxic nitrating and oxidant agent ONOO - . As for why NO
was increased, it was reported that the vessel wall of aging
rats showed an enhanced expression of iNOS isoform.28
Most importantly, our previous work reported that cardiac
iNOS expression was significantly up-regulated in aging
hearts compared with young hearts. Meanwhile, the in-
creased protein expression of iNOS was paralleled by en-
hanced iNOS activity.29 Because the iNOS isoform is capable
of producing large amounts of NO at a rate that is 100 times
greater than normal,30 up-regulation of iNOS contributes to
excessive production of NO and ONOO - in the aging heart.
Having demonstrated that TrxR is susceptible to nitration,
we further determined whether the activity of TrxR is altered
by this post-translational modification. It is worth noting that
treatment with the peroxynitrite decomposition catalyst
FeTMPyp not only decreased the nitrated TrxR protein but also
enhanced its activity, which suggested that the nitration of
TrxR may be related to its inactivity. At last we found that
FeTMPyp ameliorated the MI/R-induced myocardial apopto-
sis, lipid peroxidation, and cardiac dysfunction, suggesting that
the nitration of TrxR as a post-translational modification may
be related to its decreased activity in the aging heart, which was
involved in enhanced aging MI/R injury. Moreover, FeTMPyp
preserved Trx activity as well as TrxR activity in the aging heart
subject to MI/R, which was consistent with our previously
published results that another peroxynitrite decomposition
catalyst FP-15 increased Trx activity in aging heart.9 TrxR was
named for its ability to reduce oxidized Trxs and is necessary
for the biological activity of Trx. Therefore, both TrxR and Trx
disturbed expression and/or activity play critical roles in aging,
and the Trx system may be a novel therapeutic target for age-
associated diseases, such as cardiovascular disease.
Our results demonstrate that TrxR activity is decreased in
the aging heart subjected to MI/R, which might be related to
its nitrative modification. Blocking ONOO- production and
inhibiting TrxR inactivation significantly prevented the aging
heart from MI/R injury, which suggested that inhibiting
nitration and restoring TrxR activity might be a therapy to
attenuate enhanced MI/R injury in aging patient.
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